[ad_1]
Johnson & Johnson (NYSE:JNJ – Get Rating) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, October 18th. Analysts expect Johnson & Johnson to post earnings of $2.57 per share for the quarter. Johnson & Johnson has set its FY22 guidance at $10.00-10.10 EPS and its FY 2022 guidance at $10.00-$10.10 EPS. Individual interested in registering for the company’s earnings conference call can do so using this link.
Johnson & Johnson (NYSE:JNJ – Get Rating) last released its earnings results on Tuesday, July 19th. The company reported $2.59 EPS for the quarter, topping the consensus estimate of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14 % and a net margin of 19.21%. The business had revenue of $24.02 billion for the quarter, compared to the consensus estimate of $23.85 billion. During the same period in the previous year, the company posted $2.48 earnings per share. The company’s revenue for the quarter was up 3.0% compared to the same quarter last year. On average, analysts expect Johnson & Johnson to post $10 EPS for the current fiscal year and $11 EPS for the next fiscal year.
Johnson & Johnson Trading Up 0.1%
NYSE:JNJ opened at $160.41 on Tuesday. The company’s 50-day moving average price is $165.82 and its 200-day moving average price is $173.35. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.37. Johnson & Johnson has a 52 week low of $155.72 and a 52 week high of $186.69. The stock has a market cap of $421.75 billion, a price-to-earnings ratio of 23.35, a PEG ratio of 3.03 and a beta of 0.56.
Johnson & Johnson declared that its board has authorized a stock repurchase plan on Wednesday, September 14th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the company to purchase up to 1.2% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its shares are undervalued.
Johnson & Johnson Announces Dividend
The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, September 6th. Investors of record on Tuesday, August 23rd were issued a $1.13 dividend. The ex-dividend date of this dividend was Monday, August 22nd. This represents a $4.52 annualized dividend and a yield of 2.82%. Johnson & Johnson’s payout ratio is 65.79%.
Wall Street Analyst Weigh In
A number of analysts have commented on JNJ shares. Daiwa Capital Markets initiated coverage on Johnson & Johnson in a research report on Wednesday, June 22nd. They issued an “outperform” rating for the company. Citigroup reduced their price objective on shares of Johnson & Johnson from $201.00 to $198.00 in a research note on Wednesday, October 5th. Wells Fargo & Company upped their target price on shares of Johnson & Johnson from $190.00 to $195.00 and gave the stock an “overweight” rating in a report on Wednesday, July 13th . UBS Group decreased their price target on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Finally, Morgan Stanley cut their target price on Johnson & Johnson from $174.00 to $173.00 and set an “equal weight” rating for the company in a research report on Monday, September 12th. Four research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company’s stock. Ba sed on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $189.44.
Institutional Investors Weigh In On Johnson & Johnson
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Private Capital Management LLC purchased a new stake in Johnson & Johnson during the 1st quarter valued at $213,000. Charles Schwab Investment Advisory Inc. raised its position in Johnson & Johnson by 40.6% in the 1st quarter. Charles Schwab Investment Advisory Inc. now owns 1,862 shares of the company’s stock worth $330,000 after purchasing an additional 538 shares during the period. qPULA Trading Management LP purchased a new position in shares of Johnson & Johnson during the first quarter valued at approximately $422,000. KC Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 21.7% during the first quarter. KC Investment Advisors LLC now owns 2,808 shares of the company’s stock valued at $498,000 after buying an An additional 501 shares during the last quarter. Finally, Tatro Capital LLC lifted its stake in shares of Johnson & Johnson by 2.3% durin g the 1st quarter. Tatro Capital LLC now owns 3,059 shares of the company’s stock worth $542,000 after acquiring an additional 69 shares during the last quarter. 68.59% of the stock is currently owned by hedge funds and other institutional investors.
About Johnson & Johnson
(Get Rating)
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company’s Consumer Health segment offers baby care products under the JOHNSON’S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat’s editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Johnson & Johnson, you’ll want to hear this.
MarketBeat keeps track of Wall Street’s top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on… and Johnson & Johnson wasn’t on the list.
While Johnson & Johnson currently has a “Moderate Buy” rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
[ad_2]
Source link